Vigilex BV Report issue

For profit Phase 2
Founded: Rotterdam Netherlands (1997)
Status: Acquired by Xendo BV (2013) → now ProPharma (2018)

Organization Overview

First Clinical Trial
2006
NCT00727324
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

bovine intestinal alkaline phosphatase (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1